You just read:

Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole

News provided by

Novartis Pharmaceuticals Corporation

Dec 09, 2016, 08:30 ET